Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Depreciation and Depletion (2019 - 2026)

Kymera Therapeutics has reported Depreciation and Depletion over the past 8 years, most recently at $1.6 million for Q1 2026.

  • Quarterly Depreciation and Depletion changed 0.0% to $1.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Mar 2026, up 10.67% year-over-year, with the annual reading at $8.3 million for FY2025, 12.16% up from the prior year.
  • Depreciation and Depletion was $1.6 million for Q1 2026 at Kymera Therapeutics, down from $2.9 million in the prior quarter.
  • Over five years, Depreciation and Depletion peaked at $2.9 million in Q4 2025 and troughed at $700000.0 in Q1 2022.
  • The 5-year median for Depreciation and Depletion is $1.5 million (2024), against an average of $1.4 million.
  • The largest YoY upside for Depreciation and Depletion was 114185.71% in 2022 against a maximum downside of 66.64% in 2022.
  • A 5-year view of Depreciation and Depletion shows it stood at $800000.0 in 2022, then grew by 12.5% to $900000.0 in 2023, then surged by 122.22% to $2.0 million in 2024, then skyrocketed by 45.0% to $2.9 million in 2025, then plummeted by 44.83% to $1.6 million in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Depreciation and Depletion are $1.6 million (Q1 2026), $2.9 million (Q4 2025), and $2.1 million (Q3 2025).